Adaptive Biotechnologies (ADPT) Interest Expenses (2022 - 2026)

Adaptive Biotechnologies has reported Interest Expenses for 9 years, with the latest figure at $35.9 million in Q1 2026.

• Quarterly Interest Expenses rose 1095.93% year-over-year to $35.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.9 million (up 304.44% YoY) and the FY2025 annual result came in at $14.3 million, up 4.38% from the prior year.
• Interest Expenses rose to $35.9 million in Q1 2026 per ADPT's latest filing, from $3.8 million in the prior quarter.
• Over five years, Interest Expenses peaked at $145.9 million in Q1 2022 and troughed at $236000.0 in Q4 2024.
• A 5-year average of $19.8 million and a median of $3.6 million in 2023 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2022 and 2025: Interest Expenses sank 98.08% in 2022, then surged 3631.86% in 2025.
• Over 5 years, Interest Expenses stood at $2.3 million in 2022, then jumped by 30.96% to $3.0 million in 2023, then slumped by 92.16% to $236000.0 in 2024, then soared by 1516.1% to $3.8 million in 2025, then jumped by 840.69% to $35.9 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $35.9 million, $3.8 million, and $3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.